Athenex

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Athenex - China API Business engages in Active Pharmaceutical Ingredient (API) manufacturing operations.

BUFFALO, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the second quarter 2021, on Thursday, August 5, 2021, before the market opens. Athenex's management team will host a conference call and live audio webcast at 8:00am Eastern Time.

Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021

Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.

Athenex (ATNX) Skin Treatment Klisyri Gets Approval in Europe

BUFFALO, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its partner, Almirall (Almirall, S.A., BME: ALM), has received approval from the European Commission to market Klisyri® (tirbanibulin), indicated for the topical treatment of actinic keratosis (AK) of the face or scalp in adults. Almirall launched Klisyri in the U.S. in February 2021 and will be launching the product in Europe.

Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis

Athenex Inc (NASDAQ: ATNX) held a Type A meeting with the FDA during the second quarter of 2021 to discuss the deficiencies raised in the Complete Response Letter (CRL) regarding application for oral paclitaxel plus encequidar to treat metastatic breast cancer. At the meeting, Athenex provided additional analyses, including overall survival data on patient subgroups, to provide a more comprehensive summary of the risk/benefit assessment.

Athenex Issues Update On Oral Paclitaxel Application In Metastatic Breast Cancer

BUFFALO, N.Y., July 06, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company held a Type A meeting with the U.S. Food and Drug Administration (FDA) during the second quarter of 2021 to discuss the deficiencies raised in the Complete Response Letter (CRL) received in February.

Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

BUFFALO, N.Y., June 04, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that the Company presented data from a phase I pharmacokinetic study of oral docetaxel plus encequidar (“oral docetaxel”) and updated data from the phase III study of oral paclitaxel plus encequidar (“oral paclitaxel”) illustrating tumor responses by molecular subtype. The data are being presented in two posters at the American Society for Clinical Oncology 2021 (ASCO2021) Virtual Scientific Program, being held from June 4th to June 8th, 2021.

Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

European Commission Decision Anticipated by July 2021 European Commission Decision Anticipated by July 2021

Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp

BUFFALO, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, led by its Orascovery platform, today announced that investigators from Texas Children's Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine presented new clinical data from the ongoing GINAKIT2 phase 1 study of Athenex's cell therapy candidate KUR-501 targeting GD2 in neuroblastoma at the American Society of Gene & Cell Therapy (ASGCT) 24 th Annual Meeting on Friday, May 14, at 11 am ET.

Athenex, Texas Children's Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKT Cells in Neuroblastoma at ASGCT Annual Meeting

Athenex, Inc. (ATNX) CEO Johnson Lau on Q1 2021 Results - Earnings Call Transcript

The stock price of Athenex Inc (NASDAQ: ATNX) decreased 13.19% (from $4.55 to a day low of $3.95) during intraday trading. This is why it happened.

ATNX Stock: 13.19% Decrease (From $4.55 To $3.95) Intraday Explanation

Shares of Athenex (NASDAQ:ATNX) moved higher by 2.2% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 12.50% over the past year to ($0.27), which beat the estimate of ($0.40).

Athenex: Q1 Earnings Insights

Plan to Request Type A Meeting with the FDA for Oral Paclitaxel by the End of May

Athenex Provides First Quarter 2021 Corporate and Financial Update

A blockbuster acquisition could help the biotech "convert cancer into a chronic disease."

Why Athenex Stock Skyrocketed Today

The stock price of Athenex Inc (NASDAQ: ATNX) increased from $3.71 to $4.97 pre-market. This is why it happened.

ATNX Stock: From $3.71 To $4.97 (33.96% Increase) Pre-Market Explanation

Athenex Inc (NASDAQ: ATNX) shares have risen during premarket trading in reaction to acquiring Kuur Therapeutics Inc, a portfolio company of IP Group plc, for $70 million upfront. Additionally, Kuur shareholders are eligible to receive up to $115 million of milestone payments.

Athenex Shares Gain After Acquiring Kuur Therapeutics For $70M Cash, $115M Milestone Payments

BUFFALO, N.Y., May 04, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, led by its Orascovery platform, today announced that it has acquired Kuur Therapeutics, Inc., the leading developer of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies.

Athenex to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform

New York, New York--(Newsfile Corp. - May 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Athenex, Inc. ("Athenex") (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of New York. To get more information...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Athenex, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 3, 2021 - ATNX

Los Angeles, California--(Newsfile Corp. - May 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. ("Athenex" or "the Company") (NASDAQ: ATNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between August 7, 2019 and February 26, 2021, inclusive (the...

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK, May 3, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Athenex, Inc. ("Athenex" or the "Company") (NASDAQ: ATNX) from August 7, 2019 through February 26, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Western District of New York alleges violations of the Securities Exchange Act of 1934.

MAY 3, 2021 ATNX INVESTOR DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc.

New York, New York--(Newsfile Corp. - May 2, 2021) - WHY:. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the "Class Period"), of the important May 3, 2021 lead plaintiff deadline.SO WHAT: If you purchased Athenex securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

ATNX Final Deadline Tomorrow: Rosen, A Longstanding Law Firm, Encourages Athenex, Inc. Investors with Losses over $100K to Secure Counsel Before Important Monday Deadline in Securities Class Action - ATNX

New York, New York--(Newsfile Corp. - April 30, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Athenex, Inc.. (NASDAQ: ATNX)Shareholders who purchased shares of ATNX during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/athenex-inc-loss-submission-form/?id=15382&from=5CLASS PERIOD : August 7, 2019 to February...

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Athenex, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 3, 2021 - ATNX

New York, New York--(Newsfile Corp. - April 30, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Athenex, Inc. (NASDAQ: ATNX) ("Athenex") between August 7, 2019 and February 26, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/athenex-inc-loss-submission-form?prid=15374&wire=5

ATNX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Athenex, Inc.

New York, New York--(Newsfile Corp. - April 30, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Athenex, Inc. (NASDAQ: ATNX) alleging that the Company violated federal securities laws.Class Period: August 7, 2019 and February 26, 2021Lead Plaintiff Deadline: May 3, 2021Learn more about your recoverable losses in ATNX:

ATNX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 3, 2021 in the Class Action Filed on Behalf of Athenex, Inc. Limited Shareholders

Los Angeles, California--(Newsfile Corp. - April 30, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Athenex, Inc. ("Athenex" or "the Company") (NASDAQ: ATNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between August 7, 2019 and February 26, 2021, inclusive (the...

DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athenex, Inc. ("Athenex" or "the Company") (NASDAQ: ATNX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Athenex securities between August 7, 2019 and February 26, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/atn

News for Athenex Stock (ATNX)